Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $4.3800 (-5.3%) ($4.3800 - $4.3800) on Fri. Jun. 24, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.07% (three month average) | RSI | 52 | Latest Price | $4.3800(-5.3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(66%) ARKK(65%) XLC(57%) | Factors Impacting TGTX price | TGTX will decline at least -3.535% in a week (0% probabilities). VXX(-88%) VIXM(-77%) USO(-21%) TBT(-20%) UUP(-15%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.535% (StdDev 7.07%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $4.34(0.92%) | 10 Day Moving Average | $4.19(4.53%) | 20 Day Moving Average | $4.34(0.92%) | To recent high | -58.4% | To recent low | 17.3% | Market Cap | $555m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |